The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
A Genome-Wide Association Study Confirms VKORC1, CYP2C9, and CYP4F2 as Principal Genetic Determinants of Warfarin Dose
Open accessAbstract
We report the first genome-wide association study (GWAS) whose sample size (1,053 Swedish subjects) is sufficiently powered to detect genome-wide significance (p<1.5 x 10(-7)) for polymorphisms that modestly alter therapeutic warfarin dose. The anticoagulant drug warfarin is widely prescribed for reducing the risk of stroke, thrombosis, pulmonary embolism, and coronary malfunction. However, Caucasians vary widely (20-fold) in the dose needed for therapeutic anticoagulation, and hence prescribed doses may be too low (risking serious illness) or too high (risking severe bleeding). Prior work established that approximately 30% of the dose variance is explained by single nucleotide polymorphisms (SNPs) in the warfarin drug target VKORC1 and another approximately 12% by two non-synonymous SNPs (*2, *3) in the cytochrome P450 warfarin-metabolizing gene CYP2C9. We initially tested each of 325,997 GWAS SNPs for association with warfarin dose by univariate regression and found the strongest statistical signals (p<10(-78)) at SNPs clustering near VKORC1 and the second lowest p-values (p<10(-31)) emanating from CYP2C9. No other SNPs approached genome-wide significance. To enhance detection of weaker effects, we conducted multiple regression adjusting for known influences on warfarin dose (VKORC1, CYP2C9, age, gender) and identified a single SNP (rs2108622) with genome-wide significance (p = 8.3 x 10(-10)) that alters protein coding of the CYP4F2 gene. We confirmed this result in 588 additional Swedish patients (p<0.0029) and, during our investigation, a second group provided independent confirmation from a scan of warfarin-metabolizing genes. We also thoroughly investigated copy number variations, haplotypes, and imputed SNPs, but found no additional highly significant warfarin associations. We present power analysis of our GWAS that is generalizable to other studies, and conclude we had 80% power to detect genome-wide significance for common causative variants or markers explaining at least 1.5% of dose variance. These GWAS results provide further impetus for conducting large-scale trials assessing patient benefit from genotype-based forecasting of warfarin dose.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PLINK: a tool set for whole-genome association and population-based linkage analyses.
Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M. A. R., Bender, D., Maller, J., Sklar, P., de Bakker, P. I. W., Daly, M. J., et al. (2007) · The American Journal of Human Genetics · doi:10.1086/519795 · Cited by 34,089 · cited 3×
“We also tested haplotypes for association with warfarin dose by two approaches: (1) each subject’s warfarin dose residual (difference between observed and predicted dose based on the full multivariate regression model containing CYP4F2) was considered a quantitative trait value and tested for association with haplotyp…”
MethodGenome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls
The Wellcome Trust Case Control Consortium, Management Committee, Burton, P. R., Clayton, D. G., Cardon, L. R., Craddock, N., Deloukas, P., Duncanson, A., Kwiatkowski, D. P., McCarthy, M. I., et al. (2007) · Nature · doi:10.1038/nature05911 · Cited by 9,442
Self-citationA second generation human haplotype map of over 3.1 million SNPs
The International HapMap Consortium (2007) · Nature · doi:10.1038/nature06258 · Cited by 4,438
Browning, S. R., & Browning, B. L. (2007) · The American Journal of Human Genetics · doi:10.1086/521987 · Cited by 3,210
Detection of large-scale variation in the human genome
Iafrate, A. J., Feuk, L., Rivera, M. N., Listewnik, M. L., Donahoe, P. K., Qi, Y., Scherer, S. W., & Lee, C. (2004) · Nature Genetics · doi:10.1038/ng1416 · Cited by 2,892
The Wellcome Trust Case Control Consortium, U.K.
Mossman, K. (2008) · Scientific American · doi:10.1038/scientificamerican0108-42a · Cited by 2,684
Kendall's Advanced Theory of Statistics.
AA, Stuart, A., & Ord, K. (1995) · Journal of the American Statistical Association · doi:10.2307/2291187 · Cited by 2,619
Circular binary segmentation for the analysis of array-based DNA copy number data
Olshen, A. B., Venkatraman, E. S., Lucito, R., & Wigler, M. (2004) · Biostatistics · doi:10.1093/biostatistics/kxh008 · Cited by 2,325
Weir, B. S. (1997) · Biometrics · doi:10.2307/2533134 · Cited by 2,263
Haley, C. S., & Knott, S. A. (1992) · Heredity · doi:10.1038/hdy.1992.131 · Cited by 1,991
Effect of VKORC1 Haplotypes on Transcriptional Regulation and Warfarin Dose
Rieder, M. J., Reiner, A. P., Gage, B. F., Nickerson, D. A., Eby, C. S., McLeod, H. L., Blough, D. K., Thummel, K. E., Veenstra, D. L., & Rettie, A. E. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044503 · Cited by 1,399
Linkage Disequilibrium in Humans: Models and Data
Pritchard, J. K., & Przeworski, M. (2001) · The American Journal of Human Genetics · doi:10.1086/321275 · Cited by 1,274
Aithal, G. P., Day, C. P., Kesteven, P. J., & Daly, A. K. (1999) · The Lancet · doi:10.1016/s0140-6736(98)04474-2 · Cited by 1,243
Interval mapping of multiple quantitative trait loci.
Jansen, R. C. (1993) · Genetics · doi:10.1093/genetics/135.1.205 · Cited by 850
Anderson, J. L., Horne, B. D., Stevens, S. M., Grove, A. S., Barton, S., Nicholas, Z. P., Kahn, S. F. S., May, H. T., Samuelson, K. M., Muhlestein, J. B., et al. (2007) · Circulation · doi:10.1161/circulationaha.107.737312 · Cited by 727
D'Andrea, G., D'Ambrosio, R. L., Di Perna, P., Chetta, M., Santacroce, R., Brancaccio, V., Grandone, E., & Margaglione, M. (2005) · Blood · doi:10.1182/blood-2004-06-2111 · Cited by 699
The largest prospective warfarin-treated cohort supports genetic forecasting
Wadelius, M., Chen, L. Y., Lindh, J. D., Eriksson, N., Ghori, M. J. R., Bumpstead, S., Holm, L., McGinnis, R., Rane, A., & Deloukas, P. (2009) · Blood · doi:10.1182/blood-2008-04-149070 · Cited by 550
Self-citationCYP4F2 genetic variant alters required warfarin dose
Caldwell, M. D., Awad, T., Johnson, J. A., Gage, B. F., Falkowski, M., Gardina, P., Hubbard, J., Turpaz, Y., Langaee, T. Y., Eby, C., et al. (2008) · Blood · doi:10.1182/blood-2007-11-122010 · Cited by 521
High-resolution genomic profiling of chromosomal aberrations using Infinium whole-genome genotyping
Peiffer, D. A., Le, J. M., Steemers, F. J., Chang, W., Jenniges, T., Garcia, F., Haden, K., Li, J., Shaw, C. A., Belmont, J., et al. (2006) · Genome Research · doi:10.1101/gr.5402306 · Cited by 519
Inferences about Linkage Disequilibrium
Weir, B. S. (1979) · Biometrics · doi:10.2307/2529947 · Cited by 516
A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose
Cooper, G. M., Johnson, J. A., Langaee, T. Y., Feng, H., Stanaway, I. B., Schwarz, U. I., Ritchie, M. D., Stein, C. M., Roden, D. M., Smith, J. D., et al. (2008) · Blood · doi:10.1182/blood-2008-01-134247 · Cited by 481
Common VKORC1 and GGCX polymorphisms associated with warfarin dose
Wadelius, M., Chen, L. Y., Downes, K., Ghori, J., Hunt, S., Eriksson, N., Wallerman, O., Melhus, H., Wadelius, C., Bentley, D., et al. (2005) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500313 · Cited by 468
Self-citationAssociation of warfarin dose with genes involved in its action and metabolism
Wadelius, M., Chen, L. Y., Eriksson, N., Bumpstead, S., Ghori, J., Wadelius, C., Bentley, D., McGinnis, R., & Deloukas, P. (2007) · Human Genetics · doi:10.1007/s00439-006-0260-8 · Cited by 390
Self-citationCaraco, Y., Blotnick, S., & Muszkat, M. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100316 · Cited by 360
Genetic analysis of the human cytochrome P450 CYP2C9 locus
Stubbins, M. J., Harries, L. W., Smith, G., Tarbit, M. H., & Wolf, C. R. (1996) · Pharmacogenetics · doi:10.1097/00008571-199610000-00007 · Cited by 300
Hillman, M. A., Wilke, R. A., Yale, S. H., Vidaillet, H. J., Caldwell, M. D., Glurich, I., Berg, R. L., Schmelzer, J., & Burmester, J. K. (2005) · Clinical Medicine & Research · doi:10.3121/cmr.3.3.137 · Cited by 196
Pharmacogenetics of oral anticoagulants
Daly, A. K., & King, B. P. (2003) · Pharmacogenetics · doi:10.1097/00008571-200305000-00002 · Cited by 195
Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors
Wadelius, M., Sörlin, K., Wallerman, O., Karlsson, J., Yue, Q.-Y., Magnusson, P. K. E., Wadelius, C., & Melhus, H. (2004) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500220 · Cited by 191
Self-citationProspective dosing of warfarin based on cytochrome P-450 2C9 genotype
Voora, D., Eby, C., Linder, M. W., Milligan, P. E., Bukaveckas, B. L., McLeod, H. L., Maloney, W., Clohisy, J., Burnett, S. R., Grosso, L., et al. (2005) · Thrombosis and Haemostasis · doi:10.1160/th04-08-0542 · Cited by 189
Knight, K. (1999) · Chapman & Hall/CRC Texts in Statistical Science · doi:10.1201/9781584888567 · Cited by 186
A robust statistical method for case-control association testing with copy number variation
Barnes, C., Plagnol, V., Fitzgerald, T., Redon, R., Marchini, J., Clayton, D., & Hurles, M. E. (2008) · Nature Genetics · doi:10.1038/ng.206 · Cited by 175
Self-citationThe Pharmocogenomics of Warfarin: Closing in on Personalized Medicine
Rettie, A. E., & Tai, G. (2006) · Molecular Interventions · doi:10.1124/mi.6.4.8 · Cited by 160
Marioni, J. C., Thorne, N., Valsesia, A., Fitzgerald, T. W., Redon, R., Fiegler, H., Andrews, T. D., Stranger, B. E., Lynch, A. G., Dermitzakis, E. T., et al. (2007) · Genome biology · doi:10.1186/gb-2007-8-10-r228 · Cited by 132
Limdi, N. A., & Veenstra, D. L. (2008) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.28.9.1084 · Cited by 124
Incidence and predictors of severe bleeding during warfarin treatment
Lindh, J. D., Holm, L., Dahl, M., Alfredsson, L. S., & Rane, A. (2007) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-007-0048-2 · Cited by 84
Self-citationEstimating coverage and power for genetic association studies using near-complete variation data
Bhangale, T., Rieder, M. J., & Nickerson, D. A. (2008) · Nature Genetics · doi:10.1038/ng.180 · Cited by 82
Bounds and normalization of the composite linkage disequilibrium coefficient
Zaykin, D. V. (2004) · Genetic Epidemiology · doi:10.1002/gepi.20015 · Cited by 45
To what extent do scans of non-synonymous SNPs complement denser genome-wide association studies?
Evans, D. M., Barrett, J. C., & Cardon, L. R. (2008) · European Journal of Human Genetics · doi:10.1038/sj.ejhg.5202011 · Cited by 23
Cited by
The Next-Generation Sequencing Revolution and Its Impact on Genomics
Koboldt, D. C., Steinberg, K. M., Larson, D. E., Wilson, R. K., & Mardis, E. R. (2013) · Cell · doi:10.1016/j.cell.2013.09.006 · Cited by 1,037
Johnson, J. A., Gong, L., Whirl-Carrillo, M., Gage, B. F., Scott, S. A., Stein, C. M., Anderson, J. L., Kimmel, S. E., Lee, M. T. M., Pirmohamed, M., et al. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.185 · Cited by 647
Self-citationWang, L., McLeod, H. L., & Weinshilboum, R. M. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1010600 · Cited by 613
GWAS on family history of Alzheimer’s disease
Marioni, R. E., Harris, S. E., Zhang, Q., McRae, A. F., Hagenaars, S. P., Hill, W. D., Davies, G., Ritchie, C. W., Gale, C. R., Starr, J. M., et al. (2018) · Translational Psychiatry · doi:10.1038/s41398-018-0150-6 · Cited by 564
Roden, D. M., McLeod, H. L., Relling, M. V., Williams, M. S., Mensah, G. A., Peterson, J. F., & Van Driest, S. L. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31276-0 · Cited by 427
Metadata
- Authors
- Takeuchi, F., McGinnis, R., Bourgeois, S., Barnes, C., Eriksson, N., Soranzo, N., Whittaker, P., Ranganath, V., Kumanduri, V., McLaren, W., Holm, L., Lindh, J., Rane, A., Wadelius, M., & Deloukas, P.
- Venue
- PLoS Genetics
- Publisher
- Public Library of Science (PLoS)
- Published
- 2009-03-20
- Volume
- 5
- Issue
- 3
- Pages
- e1000433
- ISSN
- 1553-7390 (ISSN-L)
- 1553-7404
- OpenAlex
- W2016935074
- Cited by
- 632
- References
- 38
- FWCI
- 69.30
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.